Novartis division Sandoz recalls one lot of blood pressure drug

Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug.

The drug is made by China’s Zhejiang Huahai Pharmaceutical Co Ltd. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan.

A review was extended to other ‘sartan’ medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.

Novartis said Sandoz had not received any reports of adverse events related to this lot.

(Reporting by Arunima Banerjee in Bengaluru; Editing by Chris Reese)

  • Related Posts

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    The issue came up for discussions during the visit of Commerce Secretary Rajesh Agarwal to Buenos Aires this week. Argentina has committed to reduce barriers to facilitate the entry of…

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    The regulator had found that medicines were stored directly on the floor and flagged deficiencies in procedures for handling expired medicines.   The Maharashtra Food and Drug Administration has cancelled…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    ICT Mumbai to host official launch of RasayanAI, bringing AI-powered drug discovery to researchers

    ICT Mumbai to host official launch of RasayanAI, bringing AI-powered drug discovery to researchers

    Six fake doctors arrested in Hyderabad

    Six fake doctors arrested in Hyderabad